Nexsen Biotech Pty

The Centre for Disease Control (CDC) estimates that 2 to 3 in every 50 babies (4–6%) who develop Group B Streptococcus (GBS) disease will die and on average, about 1 in 20 non-pregnant adults with serious GBS infections dies. Working with some of the top researchers in Australia, NEXSEN BioTech is developing a cutting-edge diagnostic rapid diagnostic tool for Group B Streptococcus to provide effective patient screening. This will provide an immediately available and fully reliable diagnostic result for pregnant women all around the world, and give hope to those who live in countries without access to pathology labs.